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Abstract
Background: Frailty is characterised by increased vulnerability to falls, disability, hospitalisation and care home
admission. However, it is relatively reversible in the early stages. Older people living with frailty often have multiple
health and social issues which are difficult to address but could benefit from proactive, person-centred care.
Personalised care planning aims to improve outcomes through better self-management, care coordination and
access to community resources.
Methods: This feasibility cluster randomised controlled trial aims to recruit 400 participants from 11 general
practice clusters across Bradford and Leeds in the north of England. Eligible patients will be aged over 65 with an
electronic frailty index score of 0.21 (identified via their electronic health record), living in their own homes, without
severe cognitive impairment and not in receipt of end of life care. After screening for eligible patients, a restricted
1:1 cluster-level randomisation will be used to allocate practices to the PROSPER intervention, which will be
delivered over 12 weeks by a personal independence co-ordinator worker, or usual care. Following initial consent,
participants will complete a baseline questionnaire in their own home including measures of health-related quality
of life, activities of daily living, depression and health and social care resource use. Follow-up will be at six and 12
months. Feasibility outcomes relate to progression criteria based around recruitment, intervention delivery,
retention and follow-up. An embedded process evaluation will contribute to iterative intervention optimisation and
logic model development by examining staff training, intervention implementation and contextual factors
influencing delivery and uptake of the intervention.
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Discussion: Whilst personalised care planning can improve outcomes in long-term conditions, implementation in
routine settings is poor. We will evaluate the feasibility of conducting a cluster randomised controlled trial of
personalised care planning in a community population based on frailty status. Key objectives will be to test fidelity
of trial design, gather data to refine sample size calculation for the planned definitive trial, optimise data collection
processes and optimise the intervention including training and delivery.
Trial registration: ISRCTN12363970 – 08/11/18.
Keywords: Personalised care planning, Quality of life, Older people, Frailty, eFI, Cluster, RCT
Background and rationale
Frailty is a condition characterised by reduced biological
reserves and increased vulnerability to adverse outcomes
[1]. Frailty has characteristics of considerable clinical im-
portance, including higher reversibility at early stages
than disability and higher predictive value than chronic
disease for adverse outcomes [2]. Single disease manage-
ment frameworks and targets are less relevant for older
people living with frailty, who frequently have multi-
morbidities, personal predicaments and social problems
[3]. Current best practice suggests that care for older
people with frailty should be proactive and person-
centred, responsive to personal experiences of illness, in-
dividual priorities and predicaments [1, 4, 5].
Personalised care planning (PCP) is a promising way to
achieve this shift towards proactive, person-centred care
in frailty [4–6]. It is an anticipatory, negotiated series of
guided conversations between a patient and a suitably
trained individual to clarify goals, options and preferences
and develop an agreed plan of action [4]. The process aims
to ensure that individual values and concerns shape how
care is provided, instead of a focus on individual disease
management. In PCP, shared decision-making is a crucial
mechanism, involving a collaborative discussion of man-
agement goals (goal setting) and developing an agreed
plan for achieving these goals (action planning). Shared
decision-making enables linkage to additional mechanisms
for improving outcomes through more effective self-
management, better care coordination and better access
to community resources (social support) [4].
A 2015 Cochrane review summarised evidence from
16 international randomised controlled trials (RCTs) and
identified that PCP for long-term conditions (LCTs) can
improve physical and mental health and self-
management capability. Effects appear greater when PCP
is more comprehensive and integrated into routine care
[4]. However, the majority of studies focused on single
LTCs; no studies were identified that selected partici-
pants on the basis of frailty. Furthermore, a comprehen-
sive evaluation of PCP in the UK has identified
widespread, poor implementation [7, 8].
In the UK, the NHS long-term plan sets out the blue-
print and key ambitions for the health service over the
next 10 years [9]. The plan includes a focus on establish-
ing primary care-based multidisciplinary teams to pro-
vide tailored support for older people living with frailty
to enable them to live independently at home for longer.
It is therefore essential that promising interventions,
such as PCP, are designed to be sufficiently robust and
flexible to facilitate integration with commissioning and
provider organisations, prior to rigorous definitive trial
evaluation. Age UK, the largest voluntary sector organ-
isation representing older people in the UK, developed
an integrated personalised care planning (IPCP) service
in partnership with older people, their families and
carers. Although the service was piloted, further research
is required to optimise the service and evaluate its effect-
iveness. We have collaborated with the Age UK National
programme to optimise the IPCP service and accurately
identify those who are most likely to benefit from the
PCP based on their level of frailty and health and social
care use. The result is the Personalised Care Planning
for Older People (PROSPER) intervention, designed to
improve quality of life for older people with frailty and
reduce use of health and social care services.
Here, we describe the protocol for the feasibility trial
evaluation of PROSPER compared with usual care (UC)
to inform the design of a definitive RCT.
Aim and objectives
The overall aim of this trial will be to assess the feasibil-
ity of conducting, and to inform the design of, a defini-
tive RCT to investigate the clinical and cost-effectiveness
of PROSPER compared with UC.
Specific objectives will be to determine:
 Appropriate methods to identify, approach and
select general practices to participate in the trial.
 Appropriate methods to screen and consent
potential participants to the trial, and the extent to
which blinding can be maintained.
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 Recruitment and follow-up rates of general practices
and participants.
 How the sample size should be refined for the
definitive trial.
 How data collection processes can be optimised.
 If the intervention can be further optimised,
including through strategies to monitor and enhance
reliability and validity of the intervention (fidelity of
intervention training, delivery, receipt and
enactment).
 If proposed outcome measures are feasible and
acceptable to participants.
Methods
Trial design
PROSPER is a multi-centre, two-arm, feasibility cluster
RCT. A cluster is defined as a general practice or a
group of practices where the practices share significant
staff and/or services, or were due to merge during the
trial period. The cluster design was appropriate because
the intervention was envisaged to be a multidisciplinary
team-based intervention, delivered at the level of the
general practice. An intervention embedded within pri-
mary care would also mean there would have been a
high risk of contamination in an individually randomised
trial from practice staff treating UC participants.
We also plan to embed a mixed-methods evaluation,
informed by the MRC guidance for process evaluation of
complex interventions [10] and the NIH Behaviour
Change Consortium framework [11].
Study setting
Participants will be recruited from 11 clusters in Brad-
ford and Leeds, West Yorkshire. These locations cover a
range of multi-ethnic rural and urban populations, so
ensuring the generalisability of findings. Four of the 11
clusters will be sampled for the process evaluation.
General practice (cluster) eligibility
General practices in Bradford and Leeds who use Syst-
mOne, EMISWeb, Vision or Microtest primary care
electronic health record systems will be eligible for in-
clusion. Practices with an existing or planned PCP ser-
vice for older people with frailty that has significant
overlap with the PROSPER model will not be eligible.
Participant eligibility
Following agreements from the general practices to par-
ticipate, all patients at a practice will be screened for eli-
gibility by a practice administrative staff. The eligibility
list will be further reviewed by a lead GP to avoid in-
appropriate contact being made.
Patients meeting all of the following criteria at time of
screening will be eligible for inclusion:
 Aged 65 or over.
 Frailty defined by the electronic frailty index (eFI)
[12] score ≥ 0.21.
 Willing and able to give informed consent (or
provide a personal consultee).
Patients meeting any of the following criteria will not
be eligible for inclusion:
 Resident of a care home at time of screening.
 Registration on the Gold Standards Framework
(GSF) or end of life care.
 Coded diagnosis of severe dementia or a Montreal
Cognitive Assessment (MoCA) score of ≤ 10 at
baseline.
 Deemed inappropriate by their general practitioner
(GP) (documented reason).
 Member of the household currently or previously
participated in the trial.
Carer involvement
Where the participant or their consultee has consented
to the carer’s involvement, they will also be included.
Carers lacking the capacity to provide written informed
consent will not be included.
General practice recruitment and randomisation
A range of approaches will be used to engage with gen-
eral practices including local National Institute for
Health Research Clinical Research Networks (NIHR
CRNs), professional networks and practices listed on the
Public Health England (PHE) website [13].
Practices will be randomised on a 1:1 basis either to
implement the intervention or continue with usual care
(UC) only, using an algorithm for covariate-constrained
randomisation to achieve balanced allocation between
the trial arms on sample size and baseline characteristics
expected to be potential confounding factors [14]. Ran-
domisation will be performed by the statistical team at
the Clinical Trials Research Unit (CTRU). Following
randomisation, the CTRU will inform the practice man-
ager of the allocation to allow trial procedures to be im-
plemented. Knowledge of the allocation will be
restricted to staff in the practice multidisciplinary team
(MDT) who will be involved in the delivery of the inter-
vention. MDTs may include a variety of staff from GPs
to community matrons. We will seek to maintain blind-
ing of practice staff not directly involved in intervention
delivery. Instances of un-blinding will be recorded.
Participant recruitment/randomisation
To allow for scheduling of the intervention delivery and
ensure that a similar number of participants are re-
cruited from each general practice, eligible participants
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will be invited to consent to data collection in a phased
approach. Following cluster randomisation, the CTRU
will periodically generate a random sample of eligible
participants to approach. Eligibility lists from each clus-
ter will be ranked according to eFI to ensure a similar
distribution of eFI scores that are randomly sampled
across the clusters and between trial arms. For partici-
pants randomly sampled, eligibility will be re-confirmed
by a practice staff prior to sending letters of invitation
for trial participation (data collection). This process will
be the same in both trial arms. PROSPER recruitment
uses an opt-out approach, i.e. where an individual pro-
actively declines to be contacted by a researcher by
returning a negative expression of interest, to maximise
potential for participant recruitment. This will allow re-
searchers’ access to patient contact details after the opt-
out period has ended and is aligned with previous re-
search in this area [15, 16].
If there is no response to the invitation within 14 days, a
researcher blinded to allocation will contact the potential
participant by phone to discuss the study. If an individual
is interested, the researcher will make an appointment to
visit them. If not, the reason will be recorded, if possible.
Once a participant is registered in the study, the Age UK
delivery team will receive notification of those in the inter-
vention arm and proceed to make contact. Participants in
the control arm will continue to receive usual care.
The process for assignment of interventions is outlined
in Fig. 1.
Qualitative sample
A purposive sample will be informed by learning from
previous case studies of the National Age UK IPCP and
will be targeted to ensure maximum variation to support
further intervention optimisation—within the resource
constraints of a feasibility study. We anticipate that this
will be a mixture of client/carer dyads, those living alone
and from different ethnic backgrounds.
Trial consent or assent
Participant consent, recruitment and collection of base-
line data will be undertaken in the potential participant’s
own home by a researcher blind to cluster allocation.
Home visits will be made to reduce participant burden
and facilitate the assessment of capacity and cognition.
Before consent researchers will make an assessment of
the patient’s capacity to consent, using the Mental Cap-
acity Act (MCA) framework (2005) [17]. Individuals
lacking capacity to consent will not be excluded from
this study as they may still benefit from engagement
with the intervention. If a potential participant lacks cap-
acity to consent, they will be asked to nominate a per-
sonal consultee to advise on their behalf. If the potential
participant is unable to identify a personal consultee, the
GP will be requested to identify an appropriate potential
personal consultee. If a personal consultee is not avail-
able, no further contact will be made.
Following participant consent or consultee assent, re-
searchers will administer the Montreal Cognitive Assess-
ment (MoCA). Individuals scoring less than 10 will be
deemed ineligible because they would be unable to take
part in the shared decision making aspects of PCP. A
carer will be identified (if available) and after consent; in
the intervention arm, the practice administrative staff
/PIC worker will be notified which patients have been
registered.
Fig. 1 Assignment of interventions
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Reasons for declining involvement will be noted if pro-
vided. The right of a patient (and carer) to refuse partici-
pation without giving reasons will be respected.
The PROSPER intervention
PROSPER is a manualised intervention delivered to par-
ticipants in their own home by trained Age UK Staff—
Personal Independence Co-ordinators (PICs) and sup-
port workers (SW). It is based on the social cognitive
theory (SCT) which resonates closely with the tenets of
PCP in the context of frailty [18]. SCT specifies factors
governing the acquisition of competencies that can pro-
foundly affect physical and emotional wellbeing [19]. It
identifies knowledge, skills, self-efficacy, outcome expec-
tations, goals and concrete plans, and the perceived so-
cial and environmental facilitators and impediments as
core determinants influencing health habits. Therefore,
PROSPER targets confidence building and providing
older people with knowledge and skills to set personal
goals, develop appropriate action plans and personalised
problem-solving strategies. PIC workers will undertake
‘guided conversations’ and shared decision-making, de-
veloping goals and action plans with older people. Sup-
port workers will practically support older people to
achieve their goals. Both workers will be employed by a
third sector organisation but work as part of a wider
multidisciplinary team, co-located within a general
practice.
Key intervention materials include the intervention
manual and associated training package. The manual is
divided into four sections: section 1 provides an over-
view of PCP, while sections 2 and 3 provide a guide on
how to set up and deliver the service. Section 4 describes
some of the key concepts which have shaped the devel-
opment of PROSPER and includes a list of references for
further information. Section 5 (the toolkit) contains the
necessary templates of practical tools needed for set up
and delivery of the PROSPER service, e.g. job descrip-
tions, service invitation letters and action-plans. In
addition, the manual contains a list of behavioural
change techniques for use with older people identified in
a systematic review.
The training package uses blended learning (including
on-line, face to face and experiential delivery methods)
and includes background to frailty, ‘the Art of the
Guided Conversation’, motivational interviewing and a
summary of behaviour change techniques for use with
older people. Additional motivational interviewing train-
ing sessions enable reflection on the use of this approach
after initial familiarisation in the field. Intervention train-
ing will take approximately 27 h.
Core intervention activities include a guided conversa-
tion to set personal goals and develop appropriate action
plans; a two-month review to reflect on progress,
problem solve, and confirm appropriate next steps; and
‘Graduation’ (discharge from service). In line with these
activities, a minimum of three face-to-face contacts will
be made. Additional face-to-face, telephone or email
contact is expected within the 12-week intervention
period. The amount of additional contact will vary de-
pending on the needs of the older person.
We will continue to optimise the intervention using an
iterative approach, with a focus on staff training, con-
textual factors and implementation in preparation for a
definitive clinical trial.
Consent to the process evaluation
All participants will be recruited to the process evalu-
ation by an independent researcher not involved in base-
line or follow-up data collection for the feasibility trial.
Consent will be sought from each participating individ-
ual separate to the trial process. Identified clients will be
sent an information booklet about the process evaluation
at the same time as the invitation letter and intervention
service information. The PIC worker will contact partici-
pants by telephone to explain the purpose of the obser-
vations and gain verbal consent for the process
evaluation researcher to attend their first visit. Carers
and significant others will also be asked for consent. De-
finitive consent for the PE will be sought by the inde-
pendent researcher at the time of the PE data collection
to avoid a significant time lapse between data collection
and consent. In addition, we will seek specific consent
for publication of any quotes and/or voice recordings for
use in dissemination. Participants have the right to with-
draw at any time and may withdraw from the process
evaluation but continue in the trial.
Usual care
Practices allocated to the control arm will continue to
provide usual care, defined as ‘The wide range of care
that is provided in a community whether it is adequate
or not, without a normative judgement’ [20]. To increase
external validity and relevance of trial findings to clinical
practice, we will use an unrestricted usual care approach
in both control and intervention arms in line with prag-
matic trial design and the expected heterogeneity of
available treatments [21]. It is also anticipated that some
participants will receive disease-specific care planning
for single long-term conditions. Use of specific services
will be recorded at baseline and follow-up assessments
and documented on case report forms (CRFs) or col-
lected via routine data.
Trial data collection
Participant outcome measures will be collected via
(blinded researcher supported) self-completion question-
naires at baseline and postal follow-up questionnaires at
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6 and 12 months. Prior to sending out the follow-up
questionnaires, participant survival status and address
will be confirmed. Supported completion, by a blinded
researcher, at follow-up will be provided if a participant
loses capacity during the trial. Researchers will receive
training on all study specific assessments to ensure stan-
dardised completion and to monitor participant fatigue,
which may necessitate data collection over multiple
days.
Baseline and follow-up assessments will be ordered to
prioritise primary outcome data. Participants will also
receive a small unconditional monetary incentive (£10
gift voucher) to encourage follow-up at 12 months. We
will additionally seek to promote participant retention
through regular newsletters.
Participants, including carers, will be free to withdraw
consent at any time. Where possible, clarification on the
specific area of withdrawal, e.g. access to health and so-
cial care records will be sought, and the reason for with-
drawal will be recorded, but not obligatory. Previously
collected data will be used in the analyses.
Process evaluation data collection
We will use a range of methods to explore intervention
implementation across four intervention practices in two
geographic localities. In addition to collecting primary
data via non-participant observations, interviews and
questionnaires, we will make use of secondary data
sources wherever possible to reduce burden, i.e. CRFs
from the trial and case reports from the Age UK delivery
teams. Non-participant observations will be conducted,
with consent, during delivery staff training, ‘guided con-
versations’, two month reviews, ‘graduations’ and MDT
meetings. Semi-structured interviews will take place with
delivery team staff: MDT members (in both control and
intervention practices) and participants and their carers.
In addition, we will use the NoMAD instrument [22] to
describe how delivery and MDT staff view the interven-
tion with reference to the four constructs of the normal-
isation process theory [23]. This will elicit views about
how the intervention potentially impacts on their work
and their expectations about whether it could become
routine. It will also be used to identify any potential
areas of training that need to be tailored to accommo-
date differences in each of the stakeholder groups. All
observations and interviews will be audio or video re-
corded as appropriate.
Outcome measures
A summary of assessments and outcome measures can
be found in Table 1. If any assessment has been com-
pleted as part of usual care for a participant, the assess-
ment will not be repeated for that participant for the
purposes of the trial in order to minimise participant
burden and the potential for recall bias.
Additional delivery team activity data such as type,
number and duration of contacts will also be collected
to identify the scope and reach of the intervention.
Data will be collected from practices and PIC teams
during follow-up to determine if any change in practice
has occurred during the study period and evaluate level
of contamination.
Sample size
Formal sample size calculations are not required for
feasibility trials. However, based on PIC capacity, assum-
ing 20% of patients will meet eligibility criteria and 33%
of those will consent, we estimate an average of 25–50
patients per practice will participate in the study. A
minimum of four clusters per arm is required to allow
replication within study arm. We therefore aim to re-
cruit up to 400 participants (200 per arm) from 11 clus-
ters. A sample of this size will also allow us to estimate
recruitment and follow-up rates with a maximum likely
error of less than 10%. We originally planned to recruit
from eight clusters in two geographic localities. How-
ever, funding was uncertain in one of the localities, and
to avoid the risk of insufficient clusters, we increased the
number of clusters in the funded locality. When funding
became available in the second locality, the study team
felt the addition of another four practices would elicit
valuable contextual data for the process evaluation.
Data management
All data will be analysed and securely stored at the
CTRU. Only these data will be used in the analyses for
all abstracts and publications relating to the questions
posed within the study protocol—with the exception of
process evaluation data. All analyses will be performed
by the CTRU statistical team. All data will be stored for
10 years. Paper data will be disposed of with confidential
waste, and electronic data no longer required for analysis
will be deleted.
Statistical methods
A single final analysis is planned after the trial is closed
to recruitment and follow-up, and the trial database has
been cleaned and locked. All analyses and data summar-
ies will be conducted on the intention-to-treat (ITT)
population [24]. Participants will be analysed according
to the intervention they received. The analysis will focus
on descriptive statistics and confidence interval (CI)
estimation.
Screening, recruitment and follow-up
Recruitment strategies for general practices and partici-
pants will be evaluated by summarising the screening,
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Table 1 SPIRIT: summary and timing of assessments
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eligibility, consent/assent, registration/randomisation
processes and follow-up in line with CONSORT guid-
ance [25]. Reasons for non-participation will be reported
alongside timing of and reasons for withdrawal by study
arm to examine whether there are any systematic differ-
ences which could be attributed to the intervention.
Intervention delivery
Baseline characteristics of the participants, practices and
PIC teams will be summarised. Details of attendance at
and delivery of the training will be provided to inform
procedures for training of PICs and acceptability of
training. Intervention delivery will be assessed in line
with TiDIER [26], reporting to inform uptake, accept-
ability and fidelity alongside findings from the process
evaluation. Usual care will be summarised across all gen-
eral practices.
Refinement of the sample size
As proposed, primary outcome measures for the defini-
tive trial, the mean SF-12 and SF-36 Physical Compo-
nent Summary (PCS), and Mental Component Summary
(MCS) scores and variances will be estimated at baseline
and 12-month follow-up alongside the intra-cluster cor-
relation coefficient (ICC) and corresponding 95% confi-
dence interval (CI). Rates of deaths, withdrawal and
losses to follow-up will also inform the sample size cal-
culations for a definitive trial.
Feasibility and acceptability of outcome measures and
methods of data collection
The number and proportion of participant completed
data at baseline; 6- and 12-month follow-up will be re-
ported by arm alongside completeness rates for individ-
ual measures. Missing data will be summarised.
Participant outcome measures will be summarised at
each time point by arm along with a measure of vari-
ation. A range of CIs will be constructed for differences
between control and intervention arms at 12 months. No
formal testing will be done on these data.
Qualitative analysis
We will use framework analysis to collate and code
interview and observation data according to our original
objectives, including training, structures and adaptations.
Alongside this, we will generate further inductive themes
to add to the framework. The framework will be tested
on a sub-set of the data and refined through discussion
among the research team, before the final framework be-
ing applied to the remaining data.
The analysis aims to explore factors shaping imple-
mentation. Qualitative data, from observations, videos,
interviews and documentary analysis, will also be ex-
plored for inconsistencies in delivery and deviation from
the protocol. Findings will be used to inform the devel-
opment of the logic model using an iterative-inductive
approach to identify common themes. These will be
reviewed by the Programme Management Group and
Intervention Development Group, which will discuss
and agree any modifications required. We will use di-
rected content analysis to interrogate the PIC worker
notes for evidence of BCT, goal setting and monitoring.
Data from all sources will be triangulated to capture dif-
ferent dimensions and increase validity of the findings.
The constructs within NPT: coherence, cognitive partici-
pation, collective action and reflexive monitoring will be
employed as sensitising concepts in order to highlight
areas of implementation weakness.
Trial progression criteria
Progression criteria for a definitive RCT are based on a
traffic light system of green (proceed to RCT), amber
(review RCT design and/or intervention implementa-
tion) and red (stop and reconsider design and/or inter-
vention). Progression criteria will be assessed 12-month
post-randomisation within the areas of trial recruitment,
intervention and follow up, as detailed in Table 2.
Trial organisation and governance
Data monitoring
Data will be monitored for quality and completeness by
the Clinical Trials Research Unit (CTRU), using estab-
lished verification, validation and checking processes.
The Trial Management Group (TMG), comprising the
chief investigator (CI), CTRU team, other key co-
applicants and a GP representative will be assigned re-
sponsibility for the clinical set-up, on-going manage-
ment, promotion of the trial and for the interpretation
and publishing of the results. The TMG will be respon-
sible for auditing consent procedures, data collection,
trial end-point validation and database development.
The TMG will report to the Trial Steering Committee
(TSC) bi-annually. The TSC will comprise an independ-
ent chair, health economist and statistician.
Missing data
Missing data, except individual data items collected via
the postal questionnaires, will be chased until they are
received or confirmed as not available. Reminders will
be sent to participants if postal questionnaires are not
returned on time. Source data verification exercises on a
sample of participants may be carried out by staff from
the CTRU/Sponsor.
Harms
In this patient population of older people with frailty,
there is potential for acute illness resulting in hospital-
isation, new medical problems and deterioration of
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Table 2 Progression criteria
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existing medical problems. In recognition of this, events
fulfilling the definition of an Adverse Event (AE) or Ser-
ious Adverse Event (SAE) will not be reportable in this
study unless specified or fulfil the definition of a Related
and Unexpected Serious Adverse Event (RUSAE). All
RUSAEs will be reviewed by the CI and will be subject
to expedited reporting to the sponsor and the main Re-
search Ethics Committee (REC) by the CTRU on behalf
of the CI within 15 days.
Discussion
The PROSPER feasibility trial will provide novel evi-
dence on the feasibility of a cluster RCT evaluation of a
PCP intervention for older people living with frailty. The
study will address key methodological design consider-
ations, including fidelity of trial design and estimates to
enable definitive trial sample size calculation. Generated
evidence will also inform how data collection methods
should be optimised for trials recruiting older people
with frailty, and so will provide important information
for clinical trial design internationally. Alongside these
elements, the feasibility trial will study how the interven-
tion should be optimised in terms of training, delivery,
receipt and enactment as key fidelity considerations.
Informing design and implementation of a robust de-
finitive trail is critically important, given the focus on
transformation of services for older people living with
frailty based on best available evidence locally in Leeds
and Bradford, more widely across the UK as part of the
NHS long-term plan, and internationally.
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